Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1574112

Glaucoma - Pipeline Review, Q1 2011

Description:
Glaucoma - Pipeline Review, Q1 2011

Summary

Global Markets Direct’s, 'Glaucoma - Pipeline Review, Q1 2011', provides an overview of the Glaucoma therapeutic pipeline. This report provides information on the therapeutic development for Glaucoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Glaucoma. 'Glaucoma - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Glaucoma.
- A review of the Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Glaucoma pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Glaucoma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Glaucoma pipeline depth and focus of Glaucoma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
 
Contents:


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Glaucoma Overview
Therapeutics Development
An Overview of Pipeline Products for Glaucoma
Glaucoma Therapeutics under Development by Companies
Glaucoma Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Glaucoma Therapeutics Development
Alcon, Inc.
Bausch & Lomb Incorporated
Allergan, Inc.
Quark Pharmaceuticals, Inc.
Merck & Co., Inc.
Santen Pharmaceutical Co., Ltd.
Otsuka Pharmaceutical Co., Ltd.
Sylentis
Novagali Pharma SA
Novartis AG
Kowa Company, Ltd.
Pfizer Inc.
Sun Pharmaceutical Industries Limited
ISTA Pharmaceuticals, Inc.
OphthalmoPharma Ltd.
Inspire Pharmaceuticals, Inc.
InSite Vision Incorporated
Proneuron Biotechnologies, Inc.
Can-Fite BioPharma Ltd.
Lpath, Inc.
ACADIA Pharmaceuticals Inc.
Lexicon Pharmaceuticals, Inc.
Phytopharm Plc
Resverlogix Corp.
Sirion Therapeutics, Inc.
Summit Corporation plc
Ceregene, Inc.
AC Immune SA
Domain Therapeutics
LABORATOIRES THEA
Senju Pharmaceutical Co., Ltd.
Gene Signal International SA.
Promedior, Inc.
Surface Logix, Inc.
Inotek Pharmaceuticals Corporation
CeNeRx BioPharma, Inc.
Transtech Pharma, Inc.
Danube Pharmaceuticals, Inc.
Aerie Pharmaceuticals, Inc.
SIFI Pharma
Mimetogen Pharmaceuticals Inc.
Universities/Institutes Involved in Glaucoma Therapeutics Development
Glaucoma - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Bimatoprost + Brimonidine Tartrate + Timolol maleate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DuoTrav - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Latanoprost - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Saflutan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SNJ-2022 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
T2345 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tafluprost - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tafluprost - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
Avastin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Avastin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fluorometholone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ketorolac Acetate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Moxaverine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Subconjunctival Avastin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Glaucoma - Featured News
1. Sep 09, 2010: iSONEP Phase I Results Highlighted at Three Major Scientific Meetings
2. Sep 07, 2010: Promedior Initiates Phase IIa Clinical Study Of PRM-151 In Prevention Of Post-Surgical Scarring In Glaucoma Patients
3. Sep 06, 2010: Sylentis Receives Authorization To Commence Phase I/II Clinical Trial With SYL040012 For Treating Elevated Intraocular Pressure And Glaucoma
4. Jul 22, 2010: R-Tech Ueno Reports Change In Storage Condition For Rescula Eye Drops 0.12%
5. Jul 06, 2010: Sylentis Completes Phase I trial With SYL040012 To Treat Elevated Intraocular Pressure And Glaucoma
6. Jun 28, 2010: Quark's QPI-1007 Exhibits Neuroprotective Effects In Glaucoma Model
7. Jun 17, 2010: Inotek Initiates Multiple-Dose Phase II Clinical Trial Of INO-8875 In Patients With Glaucoma
8. May 24, 2010: Can-Fite Receives Israeli MoH Approval To Conduct Phase II Clinical Trial With CF101 In Glaucoma Patients
9. May 06, 2010: Santen Launches TAFLOTAN In Korea For Treatment Of Glaucoma And Ocular Hypertension
10. May 04, 2010: Inotek Pharmaceuticals Presents Preclinical Data At ARVO Confirming That INO-8875 Lowers IOP By Increasing Outflow through The Trabecular Meshwork
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Glaucoma, 2011
Products under Development for Glaucoma – Comparative Analysis, 2011
Comparative Analysis by Late Stage Development, 2011
Comparative Analysis by Mid Clinical Stage Development, 2011
Comparative Analysis by Early Clinical Stage Development, 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, 2011
Alcon, Inc., 2011
Bausch & Lomb Incorporated, 2011
Allergan, Inc., 2011
Quark Pharmaceuticals, Inc., 2011
Merck & Co., Inc., 2011
Santen Pharmaceutical Co., Ltd., 2011
Otsuka Pharmaceutical Co., Ltd., 2011
Sylentis, 2011
Novagali Pharma SA, 2011
Novartis AG, 2011
Kowa Company, Ltd., 2011
Pfizer Inc., 2011
Sun Pharmaceutical Industries Limited, 2011
ISTA Pharmaceuticals, Inc., 2011
OphthalmoPharma Ltd., 2011
Inspire Pharmaceuticals, Inc., 2011
InSite Vision Incorporated, 2011
Proneuron Biotechnologies, Inc., 2011
Can-Fite BioPharma Ltd., 2011
Lpath, Inc., 2011
ACADIA Pharmaceuticals Inc., 2011
Lexicon Pharmaceuticals, Inc., 2011
Phytopharm Plc, 2011
Resverlogix Corp., 2011
Sirion Therapeutics, Inc., 2011
Summit Corporation plc, 2011
Ceregene, Inc., 2011
AC Immune SA, 2011
Domain Therapeutics, 2011
LABORATOIRES THEA, 2011
Senju Pharmaceutical Co., Ltd., 2011
Gene Signal International SA., 2011
Promedior, Inc., 2011
Surface Logix, Inc., 2011
Inotek Pharmaceuticals Corporation, 2011
CeNeRx BioPharma, Inc., 2011
Transtech Pharma, Inc., 2011
Danube Pharmaceuticals, Inc., 2011
Aerie Pharmaceuticals, Inc., 2011
SIFI Pharma, 2011
Mimetogen Pharmaceuticals Inc., 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Discontinued Products

List of Figures
Number of Products under Development for Glaucoma, 2011
Products under Development for Glaucoma – Comparative Analysis, 2011
Products under Development by Companies, 2011
Products under Investigation by Universities/Institutes, 2011
Late Stage Products, 2011
Mid Clinical Stage Products, 2011
Early Clinical Stage Products, 2011
Discovery and Pre-Clinical Stage Products, 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products, 2011
Assessment by Route of Administration, 2011
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Assessment by Stage and Molecule Type, 2011
 
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/1574112

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Page 1 of 2
Printed Jul 23th 2014
11:49:51 PM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

Glaucoma - Pipeline Review, Q1 2011

Web Address

http://www.researchandmarkets.com/reports/1574112

Office Code

OC8DIMPOMQUPPR

 

Report Formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic - Single User USD 500
Electronic - Enterprisewide USD 1,500
Electronic - Site License USD 1,000

Contact information

Please enter all the information below in block capitals.

Title:
Mr Mrs Dr Miss Ms Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed Jul 23th 2014
11:49:51 PM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
 
Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Pay by Wire Transfer:

Please transfer funds to:

Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
 

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)